web analytics

The Exciting Story of Halberd Corporation (OTCMKTS: HALB)

0

Halberd Corporation (OTCMKTS: HALB) is heating up and moving northbound in recent trading attracting legions of shareholders and emerging as a volume leader in small caps. The stock was trading for as low as $0.0004 back in March and has seen recent highs of $0.0169.

HALB got a boost after the Company updated shareholders on its development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. Since recieving a $2 million grant and entering the covid research space HALB has been beefing up its BOD and recently got NFL Retired Players Association’s Chief Medical Officer Joins Halberd Corporation to Lead COVID-19 Efforts Effective Immediately. Dr. Reyes is a board certified neurologist and neuropathologist who specializes in treating diseases of the nervous system.

Halberd Corporation (OTCMKTS: HALB) previously Tykhe Corp, operating out of Jackson Center, Pennsylvania is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Halberd Corp has a joint venture on Covid-19 treatment that starts with Dr. Mitchell Felder’s patented extracorporeal therapy (US Patent 9,216,386 and US Patent 8,758,287) for the safe removal of targeted antigens from the blood and targeted organs. Dr. Felder explained, “The extracorporeal treatment is based on the process of removing the underlying basis of the disease. In the case of Covid-19, it entails removal of specific compounds which allow the virus to replicate.  We believe this technology is superior to known treatments in that it may potentially eliminate mutations of the virus.” Dr. Felder continued, “With our partners, including a leading university partner, we are now positioned to develop potential cures and mitigation for Covid-19 as well as to alleviate the global drug epidemic for our country and the world.  The joint venture includes financial commitments for funding, which if obtained, along with the continued research with our university partner is likely to develop the technology disclosed in our provisional patent application entitled ‘Method for Treating and Curing COVID-19 Infection’.  We seek to further develop and establish proof of concept with regard to these promising tools in this worldwide battle. This positions us to facilitate defenses against the growing COVID-19 menace as well as against other viral attacks.”

To Find out the inside Scoop on HALB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HALBIn August the Company secured non-dilutive, grant-based funding for their patent pending Covid-19 treatment(s). Newly formed Nonprofit Organization, Epidemiologic Solutions Corporation, a Louisiana, Internal Revenue Code Section 501(c)(3) application pending, has committed to provide funding of approximately $2,000,000, as required by Halberd Corporation and its research partners

Halberd Corporation also signed a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. The work will focus on developing antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus’ antigens from a patient’s blood. It will also focus on neutralizing the effects of antigens and development of a potential therapeutic medication. The work as ASU commenced on September 8; The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus’ antigens from a patient’s blood. Those antibodies could be multifaceted, including with regard to other viruses. The research will also focus on neutralizing the effects of antigens and developing one or more therapies.

In a press release dated September 21, Halberd Corporation released a progress update on the research being conducted in conjunction with Arizona State University researchers. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will immediately commence the identification of suitable antibodies. Dr. Chen expects to have proprietary antibodies within the next two weeks. Patent attorneys will pursue immediate protection for joint Intellectual Property ownership by Arizona State University and Halberd Corporation.

William A. Hartman, Halberd Corporation Chairman, President & CEO, and the Halberd team of doctors, Patricio Reyes, Abdon Nanhay and Edson Brito, jointly report, “We conducted the first of a planned series of technology review meetings late last week and are very impressed with the progress Dr. Chen and his team are making on our project. We look forward to having spike protein antigen antibodies in two weeks so we can begin the next phase of development – creating suitable fluorescent antibody conjugates. Fluorescence is necessary for rapid detection and elimination of the coronavirus disease antigens via our patented extracorporeal process and related provisional patents. Halberd’s patented extracorporeal process has the potential added therapeutic value of reducing or eliminating the chances of potentially dangerous side-effects associated with drugs administered internally.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $1.8 million market valuation with 317 million shares outstanding HALB is an exciting story developing in small caps; the Company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287. HALB just updated shareholders on its development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. Since receiving a $2 million grant and entering the covid research space HALB has been beefing up its BOD and recently got NFL Retired Players Association’s Chief Medical Officer Joins Halberd Corporation to Lead COVID-19 Efforts Effective Immediately. Dr. Reyes is a board certified neurologist and neuropathologist who specializes in treating diseases of the nervous system. We will be updating HALB as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with HALB.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in HALB either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.